Remove Marketing Remove Pharmaceutical Remove Therapy
article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.

article thumbnail

Biosimilar News: Stada, Alvotech Launch the First Ustekinumab Biosimilar Across Europe

The Dermatology Digest

Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. We are delighted at the launch of Uzpruvo in Europe and to be first-to-market,” adds Robert Wessman, Chief Executive Officer of Alvotech.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts

The Dermatology Digest

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. alone and no FDA approved therapies, common warts represent one of the largest unmet needs in all of dermatology. With a prevalence of approximately 22 million patients in the U.S.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

Jashin Wu, MD, founder and CEO of the Dermatology Research and Education Foundation in San Diego, CA, says that more psoriasis patients will see improvements in their condition due to the influx of new agents and biosimilars on the market. Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., And the Skin Disease of the Year Is….

article thumbnail

Oh, What a Year: TDD Looks Back at 2023 in Dermatology

The Dermatology Digest

AD: New topicals for kids “The most exciting new research is in the realm of topical therapies for atopic dermatitis (AD) in children,” shares Peter A. We will hopefully see at least one new biologic agent enter the market for AD, perhaps two,” he says. “We There’s more to look forward to as well, Dr. Lio says. “We

article thumbnail

Oh, What a Year: TDD Looks Back at 2023 in Dermatology

The Dermatology Digest

AD: New topicals for kids “The most exciting new research is in the realm of topical therapies for atopic dermatitis (AD) in children,” shares Peter A. We will hopefully see at least one new biologic agent enter the market for AD, perhaps two,” he says. “We There’s more to look forward to as well, Dr. Lio says. “We

article thumbnail

GLP-1 and Appetite Control: How it Works and Why it’s Effective

West Lake Dermatology

GLP-1’s unique ability to affect both glucose metabolism and appetite makes it a critical hormone in weight management and a target for pharmaceutical treatments aimed at curbing hunger and improving metabolic health. At the same time, GLP-1 signals to the brain that the stomach is full, helping to suppress appetite.

Medical 36